Quantbot Technologies LP Acquires New Shares in Axon Enterprise, Inc $AXON

05 Mar 2026, 05:46 by Renee Jackson · The Cerbat Gem

Quantbot Technologies LP bought a new position in shares of Axon Enterprise, Inc (NASDAQ:AXON – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,350 shares of the biotechnology company’s stock, valued at approximately $1,686,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Handelsbanken Fonder AB boosted its stake in Axon Enterprise by 9.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 65,590 shares of the biotechnology company’s stock worth $47,070,000 after acquiring an additional 5,423 shares during the last quarter. Andra AP fonden boosted its position in shares of Axon Enterprise by 38.8% during the third quarter. Andra AP fonden now owns 23,973 shares of the biotechnology company’s stock worth $17,204,000 after purchasing an additional 6,700 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Axon Enterprise by 2,541.0% in the 3rd quarter. Artisan Partners Limited Partnership now owns 96,053 shares of the biotechnology company’s stock valued at $68,931,000 after buying an additional 99,988 shares during the period. Xponance Inc. increased its position in shares of Axon Enterprise by 0.8% in the 3rd quarter. Xponance Inc. now owns 17,958 shares of the biotechnology company’s stock valued at $12,887,000 after buying an additional 147 shares in the last quarter. Finally, DNB Asset Management AS increased its position in shares of Axon Enterprise by 24.6% in the 3rd quarter. DNB Asset Management AS now owns 27,267 shares of the biotechnology company’s stock valued at $19,568,000 after buying an additional 5,379 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Insider Activity at Axon Enterprise

In related news, CFO Brittany Bagley sold 2,000 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $580.00, for a total transaction of $1,160,000.00. Following the sale, the chief financial officer owned 103,501 shares in the company, valued at approximately $60,030,580. This represents a 1.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Jennifer H. Mak sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $573.45, for a total value of $860,175.00. Following the completion of the transaction, the chief accounting officer owned 12,240 shares of the company’s stock, valued at approximately $7,019,028. This represents a 10.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 56,634 shares of company stock worth $31,534,295. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Trading Down 1.6%

NASDAQ:AXON opened at $569.81 on Thursday. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a twelve month low of $396.41 and a twelve month high of $885.91. The company has a market cap of $45.81 billion, a P/E ratio of 374.88, a price-to-earnings-growth ratio of 12.36 and a beta of 1.46. The business has a 50 day moving average price of $536.69 and a two-hundred day moving average price of $620.70.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 EPS for the quarter, topping the consensus estimate of $1.60 by $0.55. The business had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.08 earnings per share. As a group, analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

Positive Sentiment: February quarter beat: Axon reported upside to EPS and revenue (strong ARR/subscription growth and bookings highlighted on the earnings call), reinforcing the company’s SaaS-like recurring revenue narrative and supporting future growth expectations. Earnings Call Highlights
Positive Sentiment: Analyst bullishness: TD Cowen and other brokers have raised price targets and reiterated buy/outperform views after strong bookings and ARR trends (TD Cowen raised its target), giving institutional support to the bull case. Price Target Raised After Strong Bookings Growth
Neutral Sentiment: Investor outreach/visibility: Management presented at the Morgan Stanley TMT conference — useful for investor engagement but the transcript did not contain new guidance or surprises that would immediately re-rate the stock. Conference Presentation Transcript
Neutral Sentiment: Market commentary is mixed: post-earnings coverage praises growth (Axon 911, ARR) but flags a very rich forward multiple, meaning the stock needs continued execution to justify valuation. Zacks and other roundups mention Axon among featured ideas but do not change near-term fundamentals. Zacks Investment Ideas
Negative Sentiment: Insider selling: Director/insider Isaiah Fields sold 2,000 shares (~$535 avg), trimming his stake — such sales can be perceived negatively and add pressure to sentiment. SEC Filing — Fields Sale
Negative Sentiment: Additional insider sale: CAO Jennifer H. Mak sold 1,500 shares at roughly $573.45, further signaling insiders taking chips off the table. SEC Filing — Mak Sale
Negative Sentiment: Aggregated coverage (TipRanks, MarketBeat) notes multiple insider sales in a short window, which can amplify investor concern about near-term selling pressure even if trades are modest. Insider Sales Coverage

Analysts Set New Price Targets

Several research firms have weighed in on AXON. Piper Sandler reduced their target price on Axon Enterprise from $753.00 to $690.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Needham & Company LLC cut their price target on shares of Axon Enterprise from $870.00 to $600.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Finally, William Blair reissued an “outperform” rating on shares of Axon Enterprise in a research report on Tuesday, February 3rd. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has a consensus rating of “Moderate Buy” and an average price target of $762.93.

Check Out Our Latest Analysis on Axon Enterprise

Axon Enterprise Company Profile

(Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.